Drug intelligence / Profile preview

DE-110

Development stage: Phase 2
Lead developer: Santen Pharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

DE-110 is a small molecule drug developed by Santen Pharmaceutical for ophthalmic use. It acts as an agonist of the glucocorticoid receptor (GR), making it a glucocorticoid receptor agonist. The primary indication under investigation has been dry eye syndromes, where its anti-inflammatory properties are expected to provide therapeutic benefit. Clinical development reached Phase 2 for dry eye syndromes[1].

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on DE-110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DE-110.

Explore the full profile